A snapshot of second-quarter 2026 performance across a varied cross-section of US equities reveals stark divergences. According to company filings, semiconductor testing and energy refining operations are surpassing analyst estimates, while targeted healthcare equipment manufacturers grapple with lowered guidance and regulatory headwinds.

PBF Energy (PBF.US)

The independent oil refiner posted USD 11.68 billion in revenue for the second quarter of 2026, marking a 56.2% increase year-over-year that topped estimates. Earnings per share came in at USD 6.22, significantly exceeding the USD 3.49 projected by analysts. Management indicated that with approximately 5 million to 6 million barrels per day of global refining capacity remaining offline, refining margins are expected to stay above mid-cycle levels for the foreseeable future. The company also reduced its net debt by more than USD 1.4 billion.

FormFactor (FORM.US)

Shares of the semiconductor testing equipment provider have recorded notable gains recently, including a 17% advance following its July earnings release. FormFactor reported second-quarter sales of USD 258.24 million and EPS of USD 0.82, beating consensus estimates. The company recently joined the Russell 1000 Index and formed a strategic partnership with Keystone Microtech to bolster next-generation semiconductor capabilities in Taiwan.

Air Products and Chemicals (APD.US)

The industrial gas supplier reported fiscal third-quarter 2026 revenue of USD 3.16 billion, up 4.6% from a year earlier, alongside an EPS beat at USD 3.47. The company has been pivoting back to its core industrial gas operations, recently recording a charge to exit the Louisiana Clean Energy Complex project. Air Products is targeting fiscal fourth-quarter EPS between USD 3.55 and USD 3.65.

Expensify (EXFY.US)

While total net revenue for the expense management platform slipped 5% to USD 33.9 million in the second quarter, interchange revenue from the Expensify Card bucked the trend, rising 12% to USD 5.9 million. Despite a slight decline in paid members to 640,000, management reaffirmed full-year 2026 free cash flow guidance of USD 12 million to USD 14 million. Citizens recently upgraded the stock, projecting a return to growth over the next 12 months as Expensify scales its AI-automated features.

CVRx (CVRX.US)

The heart failure medical device maker is facing significant pressure following the disclosure of a civil investigative demand from the US Department of Justice regarding its sales and marketing practices. The stock previously dropped nearly 60% on the news, prompting multiple shareholder investigations. Although second-quarter revenue grew 16% to USD 15.7 million, CVRx lowered its full-year revenue forecast to a range of USD 58 million to USD 60 million, citing execution challenges.

Verastem Oncology (VSTM.US)

The biopharmaceutical company reported an increase in second-quarter revenue to USD 40.1 million, up from USD 2.1 million a year ago, driven largely by USD 25.1 million in net product revenue from its AVMAPKI FAKZYNJA CO-PACK. Verastem has now initiated dosing in three Phase 2 registration-directed trials for its VS-7375 candidate, with updated clinical data across multiple cancer types expected in October 2026.

Market Landscape & Other Monitored Equities

Across the broader market structure, several other entities are navigating quieter operational cycles. Digital services provider GDCA (GDC.US), clinical-stage vaccine developer GeoVax Labs (GOVX.US), and industrial equipment manufacturer Maruyama Manufacturing (MARUY.US) remain in a holding pattern as investors await updated fundamental data. Meanwhile, the leveraged volatility instrument 2x Long VIX Futures ETF (UVIX.US) continues to see trading volume as a macro hedging tool, reflecting ongoing risk pricing amidst the current cross-sector valuation divergence.

This article does not constitute investment advice.